Truist Financial Corp Buys 9,180 Shares of DaVita Inc. (NYSE:DVA)

Truist Financial Corp boosted its position in shares of DaVita Inc. (NYSE:DVA) by 54.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,068 shares of the company’s stock after buying an additional 9,180 shares during the period. Truist Financial Corp’s holdings in DaVita were worth $2,731,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. PNC Financial Services Group Inc. increased its stake in DaVita by 1.0% in the third quarter. PNC Financial Services Group Inc. now owns 15,088 shares of the company’s stock valued at $1,426,000 after acquiring an additional 153 shares during the last quarter. Kingswood Wealth Advisors LLC acquired a new position in shares of DaVita during the 4th quarter worth $2,831,000. Raymond James & Associates lifted its position in shares of DaVita by 135.2% during the 4th quarter. Raymond James & Associates now owns 34,376 shares of the company’s stock worth $3,601,000 after buying an additional 19,759 shares during the last quarter. Handelsbanken Fonder AB grew its position in DaVita by 108.8% in the fourth quarter. Handelsbanken Fonder AB now owns 16,700 shares of the company’s stock valued at $1,749,000 after acquiring an additional 8,700 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its stake in DaVita by 27.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 50,981 shares of the company’s stock worth $5,341,000 after acquiring an additional 11,097 shares in the last quarter. 90.12% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. UBS Group lifted their price target on shares of DaVita from $113.00 to $134.00 and gave the company a “buy” rating in a report on Wednesday, February 14th. StockNews.com cut DaVita from a “strong-buy” rating to a “buy” rating in a research note on Monday. Barclays boosted their price objective on DaVita from $133.00 to $150.00 and gave the stock an “equal weight” rating in a research report on Monday. Truist Financial lifted their price target on DaVita from $130.00 to $135.00 and gave the company a “hold” rating in a research note on Tuesday, February 20th. Finally, TheStreet raised DaVita from a “c+” rating to a “b-” rating in a research note on Wednesday, February 7th. Two research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $121.33.

DaVita Trading Up 0.7 %

NYSE DVA opened at $137.79 on Wednesday. DaVita Inc. has a 12 month low of $71.51 and a 12 month high of $145.04. The company has a current ratio of 1.43, a quick ratio of 1.37 and a debt-to-equity ratio of 7.95. The firm has a market capitalization of $12.08 billion, a PE ratio of 15.66, a price-to-earnings-growth ratio of 1.17 and a beta of 1.04. The business’s 50-day moving average price is $134.15 and its two-hundred day moving average price is $113.89.

DaVita (NYSE:DVA) last released its earnings results on Thursday, May 2nd. The company reported $2.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.95 by $0.43. The business had revenue of $3.07 billion during the quarter, compared to the consensus estimate of $3.03 billion. DaVita had a net margin of 6.61% and a return on equity of 68.52%. The company’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.58 EPS. On average, analysts expect that DaVita Inc. will post 9.49 EPS for the current year.

Insider Activity at DaVita

In other DaVita news, CEO Javier Rodriguez sold 67,603 shares of the stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the completion of the sale, the chief executive officer now directly owns 488,697 shares in the company, valued at approximately $61,629,578.67. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other DaVita news, CEO Javier Rodriguez sold 67,603 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the transaction, the chief executive officer now directly owns 488,697 shares in the company, valued at approximately $61,629,578.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider James O. Hearty sold 26,164 shares of DaVita stock in a transaction on Friday, February 16th. The shares were sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the completion of the sale, the insider now owns 20,264 shares of the company’s stock, valued at approximately $2,424,384.96. The disclosure for this sale can be found here. Insiders have sold a total of 134,540 shares of company stock worth $16,551,071 over the last quarter. Company insiders own 1.40% of the company’s stock.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.